IL240612A0 - Tricyclic heterocycles as anti-cancer agents - Google Patents
Tricyclic heterocycles as anti-cancer agentsInfo
- Publication number
- IL240612A0 IL240612A0 IL240612A IL24061215A IL240612A0 IL 240612 A0 IL240612 A0 IL 240612A0 IL 240612 A IL240612 A IL 240612A IL 24061215 A IL24061215 A IL 24061215A IL 240612 A0 IL240612 A0 IL 240612A0
- Authority
- IL
- Israel
- Prior art keywords
- anticancer agents
- tricyclic heterocycles
- tricyclic
- heterocycles
- anticancer
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766387P | 2013-02-19 | 2013-02-19 | |
| PCT/US2014/017127 WO2014130534A1 (en) | 2013-02-19 | 2014-02-19 | Tricyclic heterocycles as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL240612A0 true IL240612A0 (en) | 2015-10-29 |
Family
ID=51391756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL240612A IL240612A0 (en) | 2013-02-19 | 2015-08-17 | Tricyclic heterocycles as anti-cancer agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9796717B2 (OSRAM) |
| EP (1) | EP2958565A4 (OSRAM) |
| JP (1) | JP2016508521A (OSRAM) |
| KR (1) | KR20150119390A (OSRAM) |
| CN (1) | CN105073117A (OSRAM) |
| AU (1) | AU2014219042A1 (OSRAM) |
| BR (1) | BR112015019818A2 (OSRAM) |
| CA (1) | CA2901493A1 (OSRAM) |
| IL (1) | IL240612A0 (OSRAM) |
| MX (1) | MX2015010407A (OSRAM) |
| RU (1) | RU2015139700A (OSRAM) |
| SG (1) | SG11201506450RA (OSRAM) |
| WO (1) | WO2014130534A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015138496A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
| WO2015138500A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| WO2017044575A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| JP6955485B2 (ja) * | 2015-09-09 | 2021-10-27 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| JP6966425B2 (ja) * | 2015-09-09 | 2021-11-17 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| WO2023164940A1 (zh) * | 2022-03-04 | 2023-09-07 | 中国福利会国际和平妇幼保健院 | 氮杂吩噻嗪类化合物及其在制备治疗子宫内膜癌的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634766A (en) * | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
| GB8510680D0 (en) * | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| US5834462A (en) | 1993-07-26 | 1998-11-10 | Eisai Co., Ltd. | Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives |
| EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | DIARYLSULTAME DERIVATIVES |
| US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| CN1267290A (zh) * | 1997-06-17 | 2000-09-20 | 先灵公司 | 新的法呢基－蛋白转移酶的三环磺酰胺抑制剂 |
| US6583138B1 (en) * | 1998-02-27 | 2003-06-24 | Eisai Co., Ltd. | Heterocyclic-ring condensed benzothiazine compound |
| CN1558907A (zh) * | 2000-09-20 | 2004-12-29 | ���鹫˾ | 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑 |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| JP4568361B2 (ja) | 2005-04-22 | 2010-10-27 | アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| CA2844985A1 (en) | 2011-08-16 | 2013-02-21 | Mt. Sinai School Of Medicine | Tricyclic compounds as anticancer agents |
| US9701676B2 (en) | 2012-08-24 | 2017-07-11 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
| WO2015138496A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
| WO2015138500A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
-
2014
- 2014-02-19 SG SG11201506450RA patent/SG11201506450RA/en unknown
- 2014-02-19 CA CA2901493A patent/CA2901493A1/en not_active Abandoned
- 2014-02-19 CN CN201480009539.1A patent/CN105073117A/zh active Pending
- 2014-02-19 KR KR1020157025564A patent/KR20150119390A/ko not_active Withdrawn
- 2014-02-19 US US14/768,632 patent/US9796717B2/en active Active
- 2014-02-19 WO PCT/US2014/017127 patent/WO2014130534A1/en not_active Ceased
- 2014-02-19 AU AU2014219042A patent/AU2014219042A1/en not_active Abandoned
- 2014-02-19 BR BR112015019818A patent/BR112015019818A2/pt not_active IP Right Cessation
- 2014-02-19 JP JP2015558219A patent/JP2016508521A/ja active Pending
- 2014-02-19 EP EP14754200.5A patent/EP2958565A4/en not_active Withdrawn
- 2014-02-19 MX MX2015010407A patent/MX2015010407A/es unknown
- 2014-02-19 RU RU2015139700A patent/RU2015139700A/ru not_active Application Discontinuation
-
2015
- 2015-08-17 IL IL240612A patent/IL240612A0/en unknown
-
2017
- 2017-09-19 US US15/708,916 patent/US20180002339A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9796717B2 (en) | 2017-10-24 |
| SG11201506450RA (en) | 2015-09-29 |
| CN105073117A (zh) | 2015-11-18 |
| EP2958565A1 (en) | 2015-12-30 |
| RU2015139700A (ru) | 2017-03-27 |
| KR20150119390A (ko) | 2015-10-23 |
| WO2014130534A1 (en) | 2014-08-28 |
| BR112015019818A2 (pt) | 2017-07-18 |
| EP2958565A4 (en) | 2016-07-27 |
| JP2016508521A (ja) | 2016-03-22 |
| US20180002339A1 (en) | 2018-01-04 |
| AU2014219042A1 (en) | 2015-09-17 |
| MX2015010407A (es) | 2015-10-26 |
| US20150376191A1 (en) | 2015-12-31 |
| CA2901493A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210212T8 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| ZA201506880B (en) | Quinolines derivatives as novel anticancer agents | |
| GB2533229B (en) | Mineral-encapsulated tracers | |
| ZA201600792B (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| IL243323A0 (en) | Anti-cancer combinations | |
| IL240612A0 (en) | Tricyclic heterocycles as anti-cancer agents | |
| PL3071578T3 (pl) | Tricykliczne związki piperydyny | |
| PL3022200T3 (pl) | Nowe środki antymalaryczne | |
| GB201603522D0 (en) | Pyrazolochalcones as potential anticancer agents | |
| GB2511105B (en) | Sock Construction | |
| GB201300649D0 (en) | Cyclization | |
| GB201317949D0 (en) | Anticancer treatments | |
| GB201314504D0 (en) | Anticancer treatments | |
| ZA201403137B (en) | Sock | |
| GB201313695D0 (en) | Appetite-suppressant composition | |
| GB201314961D0 (en) | Spirocyclic derivatives | |
| GB201314965D0 (en) | Spirocyclic derivatives | |
| GB201311202D0 (en) | Tracers | |
| GB201307703D0 (en) | Complexes |